16:12 EST Cerus (CERS) raises FY25 product revenue view to $202M-$204M from $200M-$203M
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS:
- CERS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cerus Corporation’s New Study on Trauma Hemorrhage Treatment: A Potential Game Changer?
- Cerus Corporation: Buy Rating Highlighted by Growth Potential and Undervaluation
- Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease
- Cerus Corporation’s New Study on INTERCEPT RBCs: Potential Market Impact